News

Mural Oncology Set to Showcase Research at SITC Annual Meeting

Mural Oncology Set to Showcase Research at SITC Annual Meeting

Mural Oncology Set to Showcase Research at SITC Annual Meeting

Mural Oncology plc (NASDAQ: MURA), a pioneering company focused on immuno-oncology, is gearing up for a significant event—the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). This important gathering will take place from November 6-10, 2024, in Houston, Texas. Mural Oncology is excited to announce they will be presenting key insights into their innovative therapies aimed at addressing critical cancer treatment challenges.

Presentations Highlighting Cutting-Edge Research

At the event, Mural Oncology plans to showcase three impactful poster presentations. The first presentation will delve into pharmacodynamic data derived from the phase 1/2 ARTISTRY-3 study, which explores less frequent dosing of nemvaleukin, their engineered interleukin-2 therapy. This research is essential, as it aims to provide deeper insight into the tumor microenvironment and how treatment with nemvaleukin can be optimized.

Details of Upcoming Presentations

Here are the specific details about the presentations Mural Oncology will be sharing at the SITC:

Tumor Microenvironment Study

Title: Tumor microenvironment pharmacodynamic effect of nemvaleukin less frequent intravenous dosing in multiple solid tumors: results from the phase 1/2 ARTISTRY-3 study
Abstract Number: 217
Presentation Date: Friday, Nov. 8

IL-18 and IL-12 Research Findings

Title: Preclinical efficacy and immune activity of half-life extended IL-18 fusion proteins resistant to IL-18BP suppression
Abstract Number: 1340
Presentation Date: Saturday, Nov. 9

Title: Modulation of IL-12p70 exposure and activity following sequential administration of tumor targeted self-assembling split IL-12 subunits
Abstract Number: 1300
Presentation Date: Saturday, Nov. 9

About Mural Oncology

Mural Oncology is utilizing its advanced protein engineering platform to create innovative immunotherapies for cancer. With an emphasis on developing cytokine therapies, the company aims to provide meaningful benefits to patients facing various types of cancer. Their lead candidate, nemvaleukin, is currently involved in trials for platinum-resistant ovarian cancer and mucosal melanoma, with results expected in the near future.

The Functionality of Nemvaleukin

Nemvaleukin is engineered to enhance the anti-tumor properties of the interleukin-2 (IL-2) pathway without the side effects commonly associated with traditional treatments. It specifically interacts with the intermediate-affinity IL-2 receptor, promoting the growth of CD8+ T cells and natural killer cells, essential for mounting effective immune responses against tumors, while minimizing the unwanted expansion of regulatory T cells.

Exploring IL-18 and IL-12 Programs

Mural Oncology is also making strides in its IL-18 program, which aims to overcome limitations posed by IL-18 binding protein, a decoy receptor that hinders the efficacy of native IL-18. Through innovative protein engineering techniques, they are working to enhance the stability and potency of IL-18.

Furthermore, the IL-12 program is equally crucial. By reformulating IL-12 into separate inactive components, Mural Oncology seeks to deliver powerful anti-cancer effects while avoiding systemic toxicity. This revolutionary approach could change how IL-12 therapies are administered and ultimately improve patient outcomes.

Contact Mural Oncology for Inquiries

If you have further questions or require more information about Mural Oncology and its programs, please reach out to:

Katie Sullivan
Email: katie.sullivan@muraloncology.com

Frequently Asked Questions

What is Mural Oncology known for?

Mural Oncology is recognized for developing innovative cytokine-based immunotherapies aimed at improving cancer treatment outcomes.

What will Mural Oncology present at the SITC meeting?

The company will present data from its ARTISTRY-3 study and findings on its IL-18 and IL-12 programs.

Why is nemvaleukin significant?

Nemvaleukin is engineered to enhance immune responses against tumors while minimizing adverse side effects, representing a promising treatment option for patients.

What is the purpose of the IL-18 program?

The IL-18 program aims to enhance the efficacy and durability of IL-18, making it more effective in stimulating immune responses against cancer.

How can I learn more about Mural Oncology?

Visit Mural Oncology's official website or contact them directly for additional information on their research and development initiatives.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 2

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
Anecdotes by Artists Brings Raw Scent Stories to Sephora

Updated Category News Views 2

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

Continue Reading
HTX's Strategic Moves in Pakistan: A Crypto Frontier

Updated Category News Views 4

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Continue Reading
Compass Unveiled: Power Revolution in Private Equity

Updated Category News Views 5

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Continue Reading
FJBio Boosts Antibody Discovery with Sapio AI

Updated Category News Views 1

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Continue Reading
Machine Grabs Prime Dallas Property Amid Apartment Boom

Updated Category News Views 1

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 3

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading
Davos Healthcare Aims to Revolutionize Hospital Ratings

Updated Category News Views 2

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Stay Safe Amid Storms: CPSC's Essential Safety Insights

Updated Category News Views 172

As tropical storms wreak havoc across regions, the importance of being vigilant cannot be overstated. The U. S. Consumer Product Safety Commission (CPSC) was there to guide through ensuring safety during these challenging times. Particularly during storms that led to power outages, understanding the risks associated with portable generators and carbon monoxide (CO) became...

Continue Reading
United Bank Earns $9 Million to Boost Affordable Housing Initiatives

Updated Category News Views 180

United Bank Secures Major Funding for Housing Projects United Bank recently announced that it has been recognized with a significant award from the U.S. Department of the Treasury's Community Development Financial Institutions Fund. The bank has secured a remarkable $9 million Capital Magnet Fund grant, marking its fifth such award since 2017. This funding is aimed at...

Continue Reading
Aces Diagnostics Unveils Major Advances in LymeSeek Testing

Updated Category News Views 164

Aces Diagnostics Partners to Enhance LymeSeek™ Test Development Aces Diagnostics Inc., a company with a focus on innovative diagnostics for Lyme disease, has announced new developments that hold great promise for the future of LymeSeek™. Through partnerships with Protavio and Repado, Aces is taking significant steps toward making its pioneering LymeSeek™ test...

Continue Reading
Nubian Updates Stake in Athena Gold's Strategic Acquisition

Updated Category News Views 142

Nubian's Investment in Athena Gold Corporation Nubian Resources Ltd. (TSX-V: NBR) has some exciting news regarding its stake in Athena Gold Corporation. The company currently owns about 31% of Athena, which includes 55 million shares, along with a crucial 1% Net Smelter Return Royalty on Excelsior Springs. This investment highlights Nubian's belief in Athena's growth...

Continue Reading
Transforming Legal Practices: Meet Trailmate's Digital Employee

Updated Category News Views 110

Revolutionizing Legal Services with Trailmate In today's competitive legal landscape, law firms are constantly seeking innovative solutions to enhance efficiency and improve client interactions. Trailmate has emerged as a groundbreaking solution with its launch of the first client-facing Digital Employee. This autonomous tool is specifically designed for law firms and...

Continue Reading